Neurogen Acquires Phase II Wyeth Compound For Parkinson’s, RLS
This article was originally published in The Pink Sheet Daily
Executive Summary
Aplindore, a partial D2 dopamine receptor agonist, may provide dosing benefits and a better side effect profile over current treatments, firm says.